Publikationen

Grundlegende Voraussetzung für die flächendeckende Verbesserung der Behandlungskonzepte ist die Publikation der Forschungsergebnisse. iOMEDICO unterstützt die internationalen Richtlinien zu Transparenz und Veröffentlichung von medizinischen Forschungsergebnissen.

Wir präsentieren unsere Daten regelmäßig auf nationalen und internationalen Kongressen. Unsere Publikationen erscheinen in wissenschaftlich renommierten, internationalen Fachzeitschriften. Autoren sind die Studienleiter, Prüfärzte mit besonders hoher Patiententeilnahme und Wissenschaftler von iOMEDICO.

TITEL
STUDIE
JAHR
Treatment sequences in patients with advanced or metastatic pancreatic cancer in German outpatient cancer centers – data from the TPK clinical cohort study.

Hegewisch-Becker, S., Aldaoud, A., Lerchenmüller, C., Scheiner-Sparna, R., Jänicke, M., Hamm, D., Marschner, N., 2017.

Oncol Res Treat 40 (suppl 3)(P825), 235.

Indikation: Pancreatic Cancer, Pankreaskarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TPK
2017
Prognostic factors for overall survival of patients with advanced renal cell carcinoma – data from the German prospective RCC-Registry.

Goebell, P.J., Müller, L., Staehler, M., Müller, Frank, M., Kruggel, L., Jänicke, M., Marschner, N., 2017.

Oncol Res Treat 40 (suppl 3)(V420), 114.

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TNK
2017
Real world effectiveness and safety of pazopanib and everolimus in metastatic renal cell carcinoma: first interim analysis of the PAZOREAL study.

Bedke, J., Welslau, M., Boegemann, M., Schostak, M., Hering-Schubert, C., Petzoldt, A., Wolf, T., Schleicher, J., Doehn, C., Grüllich, C., Grünwald, V., Steiner, T., Ehneß, R., Goebell, 2017.

Oncol Res Treat 40 (suppl 3)(P343), 97–98.

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
PAZOREAL
2017
German PASS (GS-DE-312-1750) – A prospective non-interventional post-authorization safety study (PASS) of idelalisib in Germany.

Abenhardt, W., Knauf, W., Eissmann, P., Hucke, N., van Troostenburg, A., Watzke, S., Hoechstetter, M., Rummel, M., 2017.

Oncol Res Treat 40 (suppl 3)(P524), 139–140.

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
IDELA
2017
Application study of the EQ-5D-5L in Oncology: Linking self-reported quality of life of patients with metastatic colorectal cancer to clinical data from a German tumor registry.

Borchert, K., Jacob, C., Wetzel, N., Jänicke, M., Eggers, E., Sauer, A., Marschner, N., Meise, D., Altevers, J., Mittendorf, T., Braun, S., Greiner, W., 2017.

ISPOR 20th Annual European Congress. Cancer: Clinical Outcomes Studies.

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: ISPOR / Journal: -
TKK
2017
Clinical Comparison of first-line platin chemotherapy regimens in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) using German registry data.

Haas, J., Meise, D., Ogbonnaya, A., Eaddy, M., Daeßler, K., Sandner, R., Binninger, A., Jaenicke, M., Chiabudini, M., Marschner, N., 2017.

ISPOR 20th Annual European Congress. Cancer: Clinical Outcomes Studies.

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ISPOR / Journal: -
TLK
2017
Treatment reality and outcome data of patients with advanced papillary renal cell carcinoma – data from the German prospective RCC-Registry.

Staehler, M., Müller, L., Goebell, P. J., Overkamp, F., Frank, M., Kruggel, L., Jänicke, M., Marschner, N., for the RCC Registry group, 2017.

Ann Oncol 28(Suppl.5)(909P).

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: ESMO / Journal: Annals of Oncology
TNK
2017
Prognostic factors for overall survival of patients with advanced renal cell carcinoma – data from the German prospective RCC-Registry.

Goebell, P. J., Müller, L., Staehler, M., Müller, M., Frank, M., Kruggel, L., Jänicke, M., Marschner, N., for the RCC Registry group, 2017.

Ann Oncol 28(Suppl.5)(902P). doi:10.1093/annonc/mdx365

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: ESMO / Journal: Annals of Oncology
TNK
2017
Comparison of platinum agents cisplatin and carboplatin in routine treatment of advanced NSCLC – results from prospective German TLK cohort study.

von Verschuer, U., Schnell, R., Zahn, M.-O., Eggert, J., Binninger, A., Spring, L., Jänicke, M., Marschner, N., 2017.

Ann Oncol 28 (suppl 5)(1370P), 490.

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
TLK
2017
Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): a prospective German Registry in stage IV NSCLC AIO-TRK-0315)

F. Griesinger, W. Eberhardt, N. Marschner, M. Jänicke, A. Fleitz, L. Spring, J. Sahlmann, A. Karatas, A. Hipper, W. Weichert, M. Sebastian, M. Thomas, 2017.

Ann Oncol. (2017) 28 (suppl_5): v460-v496. https://doi.org/10.1093/annonc/mdx380.086

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
CRISP
2017